(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself. - 2Rediscovering Euphoria: Individual Accounts of Conquering Despondency
- 3Two Endangered Bengal Tiger Cubs Die Days Apart at Zoo After Contracting Virus
- 4Saucony's $125 'Comfy, Stylish' Sneakers Are Now $55
- 5Figure out How to Augment Your Rooftop Substitution Speculation
- At least 55 injured in Russia after train crashes, overturns
- Ukraine's naval drones are gunning for Russia's 'shadow fleet.' A security source says a tanker just suffered a critical hit.
- Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts
- Find Exemplary Scents: An Extensive Aide
- Governors Ball 2026: Lorde, A$AP Rocky and Stray Kids set to headline
- The most effective method to Go Down Abundance through Ages with Disc Rates
- Vote In favor of Your Favored IT Administration
- Poland Crypto Bill Clears Sejm Again, Defying President — Will “Restrictive” Rules Stick?
- A soft launch, an unfollow and a lot of questions: Breaking down the 'Summer House' romance blowing up group chats
